Dyskinesia with levodopa

Type C (Chronic) reactions due to long-term exposure, e.g. analgesic nephropathy, dyskinesias with levodopa. 

CNS effects Certain adverse CNS effects (eg, dyskinesias) will occur at lower dosages and sooner during therapy with levodopa and carbidopa than with levodopa alone. 

Adverse reactions occurring in at least 3% of patients with advanced PD (with levodopa) included the following abdominal pain accidental injury accommodation abnormalities akathisia amnesia arthritis asthenia chest pain confusion constipation diarrhea dizziness dream abnormalities dry mouth dyskinesia dyspnea dystonia extrapyramidal syndrome falls flushing gait... 

Amantadine is an old drug with several pharmacological properties warranting its (empirical) use in Parkinson s disease facilitation of dopamine release, blockade of dopamine re-uptake, anticholinergic effect, blockade of NMDA receptors. Amantadine is usually employed early in the disease process (monotherapy, 100 mg b.i.d.) and most often in combination with levodopa in more advanced stage disease (anti-dyskinesia effect ). 

For all agonists, it is advisable to progressively increase the daily dose to reach optimal dose by plateaus. The optimal dose is titrated individually. In combination with levodopa, dopaminergic agonists lower the daily requirements for dopa and, after years of treatment, would prolong the duration of on phases and limit fluctuations in motricity and dyskinesia. Apomorphine is only indicated for patients with on-off swings, either via single-dose subcutaneous injections or a continuous infusion. 

Dyskinetic activity. A 4-week dose escalation study was performed to assess the safety and tolerability of cannabis in six patients with Parkinson s disease (PD) with levodopa (L-DOPA)-induced dyskinesia. 

Orofacial dyskinesia, though familiar with dopaminergic drugs, can apparently also occur with some anticholinergic drugs for example, it has been described with trihexyphenidyl in a patient who did not have this reaction with levodopa (SEDA-18, 160). 

Two men aged 76 and 72 years presented with advanced symptoms of Parkinson s disease and were treated with levodopa. Disabling dyskinesia occurred within days of reaching maintenance dosages of levodopa (1-1.5 g/day with benserazide). 

Neurologists from Madrid have studied 168 consecutive patients treated for at least 6 months with levodopa (57). About 10% of the patients per year developed dyskinesias over 7 years. Younger age (under 50 years) at the onset of the disease and high initial levodopa dosages (more than 600 mg/day) were the most important susceptibility factors identified. 

The most frequent adverse effect of mesulergine is dyskinesia, mostly in patients who have had similar reactions with levodopa. Orthostatic light-headedness and visual hallucinations are also common. Other adverse effects include anorexia, nausea, drowsiness, ankle swelling, insomnia, confusion, irritability, visual disturbance, chest pain, rash, and augmented body odor. 

Ouattara B, Belkhir S, Morissette M et al (2009) Implication of NMDA receptors in the antidyskinetic activity of cabergoline, Cl-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias. J Mol Neurosci 38 128-142... 

Toxicity Gastrointestinal effects include anorexia, nausea, and vomiting. Cardiovascular effects commonly include postural hypotension cardiac arrhythmias may also occur. Dyskinesias may occur with abnormal movements similar to those caused by levodopa. Behavioral effects include confusion, hallucinations, and delusions these occur more commonly with bromocriptine and pergolide than with levodopa. Like levodopa, bromocriptine and pergolide are contraindieated in patients with a history of psychosis. Miscellaneous ei ot-related effects with bromocriptine inelude pulmonary infiltrates and erythromelalgia. 

The symptoms are likely to be alleviated by continued treatment with levodopa Dyskinesias are less likely to occur if levodopa is administered with carbidopa Coadministration of muscarinic blockers prevents the occurrence of dyskinesias during treatment with levodopa... 

The form and severity of dyskinesias due to levodopa may vary widely in different patients. Dyskinesias occur in up to 80% of patients receiving levodopa for long periods. With continued treatment, dyskinesias may develop at a dose of levodopa that was previously well tolerated. They occur more commonly in patients treated with levodopa in combination with carbidopa or with other dopamine receptor agonists. Muscarinic receptor blockers do not prevent their occurrence. The answer is (B). 

Side effects were striking and seen in most patients but could be reduced with lowered doses. Dyskinesias, like those with levodopa, were most frequent, with nausea and vomiting, daytime drowsiness (with insomnia at... 

Patients with severe dyskinesias and off periods may achieve more constant blood concentrations (lower peak and higher trough concentrations) by taking a liquid formulation of levodopa with carbidopa. Each day patients make a 1 mg/mL levodopa... 

---